RecruitingPhase 4

Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion

United States200 participantsStarted 2023-12-18

Plain-language summary

The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.

Who can participate

Age range18 Years – 50 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises * ages 18 to 50 * con provide informed consent in English Exclusion Criteria: * Age under 18 or above 50 * gestational ages before 16 weeks 0 days or after 20 weeks 0 days * unable to provide written consent in English * hypertensive disorder * uncontrolled hypertension or known hypersensitivity to ergot derivatives * History of cardiac valvular disorders * history of pulmonary fibrosis * documented bipolar schizophrenia * documented allergy to medication, including lactose intolerance (placebo pill involves lactose)

What they're measuring

breast symptoms

Timeframe: 3 days post procedure and two weeks post procedure

Trial details

NCT IDNCT06123026

SponsorNorthwestern University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-06-30

View on ClinicalTrials.gov More Lactation Suppressed trials